Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The U.S. biotech, which went public last year, plans to file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer in the third quarter, based on findings from four Phase I and Phase II trials.
You may also be interested in...
Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.
Kansas City TCM Firm Persists With COVID-19 Claims Following US Regulators' Warning
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
Coronavirus Update: The Hunt For A Vaccine & Non-COVID-19 Trial Plans Go Awry
In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, we’re bringing you selected brief insights into the impact on biopharma commercial activities.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: